Pelthos Therapeutics Inc. income statement

In fiscal 2025, Pelthos Therapeutics Inc. reported revenue of $16.8m, operating income of −$32.4m (a -193.1% margin) and net income of −$43.3m, or −$23.04 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Pelthos Therapeutics Inc.: income statement, annual
Fiscal year	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	0	17	43
Cost of revenue	0	4	9
Gross profit	0	13	34
Research and development	1	1	1
Selling, general and administrative	6	42	87
Operating income	−8	−32	−58
Interest expense	1	3	7
Income before tax	−8	−51	−94
Income tax	0	−7	−7
Net income	−8	−43	−86
Diluted EPS	−$14.27	−$23.04	—
Diluted shares (average)	—	2m	—
EBITDA	−8	−32	−56

US$ millions unless shown otherwise. Fiscal quarters.

Pelthos Therapeutics Inc.: income statement, quarterly
Quarter	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	0	0	7	9	11	16
Cost of revenue	0	0	2	2	2	4
Gross profit	0	0	5	8	9	12
Research and development	0	1	0	0	0	1
Selling, general and administrative	2	3	20	18	21	28
Operating income	−2	−3	−15	−12	−13	−17
Interest expense	0	0	1	1	2	2
Income before tax	−2	−3	−17	−29	−25	−23
Income tax	0	0	−0	−7	0	0
Net income	−2	−3	−16	−22	−25	−23
Diluted EPS	−$3.21	−$5.29	−$5.30	−$8.08	−$7.57	−$6.62
EBITDA	−2	−3	−15	−12	−13	−17

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BFRI vs PTHS CPIX vs PTHS IMCC vs PTHS

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Pelthos Therapeutics Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Pelthos Therapeutics Inc.